China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to conduct a Phase I/IIa clinical study for its leukemia inhibitory factor (LIF) monoclonal antibody (mAb) in patients with advanced solid tumors.
LIF as a Target for KRAS-driven Tumors
LIF is a key target in KRAS-driven tumors, including pancreatic and colorectal cancers. Studies have demonstrated that LIF plays a crucial role in KRAS-driven cancer models, and blocking LIF with antibodies can improve treatment outcomes. JAB-BX300, Jacobio’s LIF mAb, has shown significant anti-tumor activity in the xenotransplantation model of humanized pancreatic cancer in mice, highlighting its potential in treating these aggressive cancers.
Global Standing of JAB-BX300
Currently, JAB-BX300 is the only LIF mAb in Phase II worldwide, positioning Jacobio Pharma at the forefront of LIF-targeted therapy development. This clinical study is expected to provide valuable insights into the efficacy and safety of LIF mAb in advanced solid tumors, contributing to the global effort to improve treatment options for patients with KRAS-driven malignancies.-Fineline Info & Tech
